Heidelberg Pharma AG Current Ratio Growth & History (HPHA)
Heidelberg Pharma AG's current ratio was 2.53 for fiscal 2025.
View full Heidelberg Pharma AG company overviewHeidelberg Pharma AG annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-11-30 | 2.53 | −3.42 | −57.50% |
| 2024 | 2024-11-30 | 5.95 | 3.08 | +107.69% |
| 2023 | 2023-11-30 | 2.86 | −0.28 | −9.01% |
| 2022 | 2022-11-30 | 3.15 | 2.54 | +421.38% |
| 2021 | 2021-11-30 | 0.60 | −0.53 | −46.79% |
| 2020 | 2020-11-30 | 1.13 | −0.66 | −36.78% |
| 2019 | 2019-11-30 | 1.79 | −2.03 | −53.05% |
| 2018 | 2018-11-30 | 3.82 | −3.18 | −45.40% |
| 2017 | 2017-11-30 | 7.00 | 6.09 | +668.49% |
| 2016 | 2016-11-30 | 0.91 | 0.12 | +15.25% |
| 2015 | 2015-11-30 | 0.79 | −0.13 | −14.48% |
| 2014 | 2014-11-30 | 0.92 | −0.38 | −29.28% |
| 2013 | 2013-11-30 | 1.31 | −0.20 | −13.19% |
| 2012 | 2012-11-30 | 1.50 | 1.11 | +280.14% |
| 2011 | 2011-11-30 | 0.40 | −0.13 | −24.32% |
| 2010 | 2010-11-30 | 0.52 | — | — |
Heidelberg Pharma AG quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | 5.29 | −2.45 | −31.70% |
| Q1 2026 | 2026-02-28 | 2.40 | −4.75 | −66.50% |
| Q4 2025 | 2025-11-30 | 2.53 | — | — |
| Q2 2025 | 2025-05-31 | 7.74 | — | — |
| Q1 2025 | 2025-02-28 | 7.15 | — | — |
Heidelberg Pharma AG current ratio trends
Over the last five fiscal years, Heidelberg Pharma AG's current ratio increased from 1.13 to 2.53, a change of 1.39. The latest reported quarter, Q2 2026, shows 5.29.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as reported current assets divided by reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Heidelberg Pharma AG source filings ↗Community posts
Heidelberg Pharma reports early myeloma responses and selects a development dose
Heidelberg Pharma ($HPHA) presented Phase 1 results for pamlectabart tismanitin, its experimental antibody-drug conjugate for relapsed or refractory multiple myeloma. Among 31 evaluable patients in dose cohorts five through nine, 13 respond ...